Cargando…

Individual surveillance by competing risk model for patients with hepatocellular carcinoma occurrence in all-cause cirrhosis

PURPOSE: It was of great significance to identify someone with a high risk of hepatocellular carcinoma (HCC) occurrence and make a diagnosis as early as possible. Therefore, we aimed to develop and validate a new, objective, and accurate prediction model, and convert it into a nomogram to make a per...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qi, Guo, Dandan, Gao, Wenfeng, Yuan, Chunwang, Li, Jianjun, Zhang, Yinghua, He, Ning, Zhao, Peng, Zheng, Jiasheng, Zhang, Yonghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587216/
https://www.ncbi.nlm.nih.gov/pubmed/37495731
http://dx.doi.org/10.1007/s00432-023-04911-y
_version_ 1785123312632856576
author Wang, Qi
Guo, Dandan
Gao, Wenfeng
Yuan, Chunwang
Li, Jianjun
Zhang, Yinghua
He, Ning
Zhao, Peng
Zheng, Jiasheng
Zhang, Yonghong
author_facet Wang, Qi
Guo, Dandan
Gao, Wenfeng
Yuan, Chunwang
Li, Jianjun
Zhang, Yinghua
He, Ning
Zhao, Peng
Zheng, Jiasheng
Zhang, Yonghong
author_sort Wang, Qi
collection PubMed
description PURPOSE: It was of great significance to identify someone with a high risk of hepatocellular carcinoma (HCC) occurrence and make a diagnosis as early as possible. Therefore, we aimed to develop and validate a new, objective, and accurate prediction model, and convert it into a nomogram to make a personalized prediction of cancer occurrence in cirrhotic patients with different etiologies. METHODS: The present study included 938 patients with cirrhosis from January 1, 2011, to December 31, 2012. Patients were prospectively followed-up until January 1, 2018. We used a competing risk model and the Fine–Gray test to develop and validate the prediction model and to plot a nomogram based on the model established. RESULTS: At the end of follow-up, 202 (21.5%) patients developed HCC, with a 5-year incidence of 19.0% (corrected for competing risk model). Based on the competing risk regression method, we built a prediction model including age, gender, etiology, lymphocyte, and A/G ratio. Three groups with different risks were generated on account of tertiles of the 5-year risk predicted by the model. The cumulative 1-, 3-, and 5-year incidences of HCC were 2.0%, 20.8%, and 42.3% in high-risk group, 0.9%, 10.1%, and 17.7% in medium-risk group, and 0%, 2.0%, 8.5% in low-risk group (P < 0.001). The model showed excellent discrimination and calibration in predicting the risk of HCC occurrence in patients with all-cause cirrhosis. CONCLUSION: The model could make an individual prediction of cancer occurrence and stratify patients based on predicted risk, regardless of the causes of cirrhosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-023-04911-y.
format Online
Article
Text
id pubmed-10587216
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-105872162023-10-21 Individual surveillance by competing risk model for patients with hepatocellular carcinoma occurrence in all-cause cirrhosis Wang, Qi Guo, Dandan Gao, Wenfeng Yuan, Chunwang Li, Jianjun Zhang, Yinghua He, Ning Zhao, Peng Zheng, Jiasheng Zhang, Yonghong J Cancer Res Clin Oncol Research PURPOSE: It was of great significance to identify someone with a high risk of hepatocellular carcinoma (HCC) occurrence and make a diagnosis as early as possible. Therefore, we aimed to develop and validate a new, objective, and accurate prediction model, and convert it into a nomogram to make a personalized prediction of cancer occurrence in cirrhotic patients with different etiologies. METHODS: The present study included 938 patients with cirrhosis from January 1, 2011, to December 31, 2012. Patients were prospectively followed-up until January 1, 2018. We used a competing risk model and the Fine–Gray test to develop and validate the prediction model and to plot a nomogram based on the model established. RESULTS: At the end of follow-up, 202 (21.5%) patients developed HCC, with a 5-year incidence of 19.0% (corrected for competing risk model). Based on the competing risk regression method, we built a prediction model including age, gender, etiology, lymphocyte, and A/G ratio. Three groups with different risks were generated on account of tertiles of the 5-year risk predicted by the model. The cumulative 1-, 3-, and 5-year incidences of HCC were 2.0%, 20.8%, and 42.3% in high-risk group, 0.9%, 10.1%, and 17.7% in medium-risk group, and 0%, 2.0%, 8.5% in low-risk group (P < 0.001). The model showed excellent discrimination and calibration in predicting the risk of HCC occurrence in patients with all-cause cirrhosis. CONCLUSION: The model could make an individual prediction of cancer occurrence and stratify patients based on predicted risk, regardless of the causes of cirrhosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-023-04911-y. Springer Berlin Heidelberg 2023-07-26 2023 /pmc/articles/PMC10587216/ /pubmed/37495731 http://dx.doi.org/10.1007/s00432-023-04911-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Wang, Qi
Guo, Dandan
Gao, Wenfeng
Yuan, Chunwang
Li, Jianjun
Zhang, Yinghua
He, Ning
Zhao, Peng
Zheng, Jiasheng
Zhang, Yonghong
Individual surveillance by competing risk model for patients with hepatocellular carcinoma occurrence in all-cause cirrhosis
title Individual surveillance by competing risk model for patients with hepatocellular carcinoma occurrence in all-cause cirrhosis
title_full Individual surveillance by competing risk model for patients with hepatocellular carcinoma occurrence in all-cause cirrhosis
title_fullStr Individual surveillance by competing risk model for patients with hepatocellular carcinoma occurrence in all-cause cirrhosis
title_full_unstemmed Individual surveillance by competing risk model for patients with hepatocellular carcinoma occurrence in all-cause cirrhosis
title_short Individual surveillance by competing risk model for patients with hepatocellular carcinoma occurrence in all-cause cirrhosis
title_sort individual surveillance by competing risk model for patients with hepatocellular carcinoma occurrence in all-cause cirrhosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587216/
https://www.ncbi.nlm.nih.gov/pubmed/37495731
http://dx.doi.org/10.1007/s00432-023-04911-y
work_keys_str_mv AT wangqi individualsurveillancebycompetingriskmodelforpatientswithhepatocellularcarcinomaoccurrenceinallcausecirrhosis
AT guodandan individualsurveillancebycompetingriskmodelforpatientswithhepatocellularcarcinomaoccurrenceinallcausecirrhosis
AT gaowenfeng individualsurveillancebycompetingriskmodelforpatientswithhepatocellularcarcinomaoccurrenceinallcausecirrhosis
AT yuanchunwang individualsurveillancebycompetingriskmodelforpatientswithhepatocellularcarcinomaoccurrenceinallcausecirrhosis
AT lijianjun individualsurveillancebycompetingriskmodelforpatientswithhepatocellularcarcinomaoccurrenceinallcausecirrhosis
AT zhangyinghua individualsurveillancebycompetingriskmodelforpatientswithhepatocellularcarcinomaoccurrenceinallcausecirrhosis
AT hening individualsurveillancebycompetingriskmodelforpatientswithhepatocellularcarcinomaoccurrenceinallcausecirrhosis
AT zhaopeng individualsurveillancebycompetingriskmodelforpatientswithhepatocellularcarcinomaoccurrenceinallcausecirrhosis
AT zhengjiasheng individualsurveillancebycompetingriskmodelforpatientswithhepatocellularcarcinomaoccurrenceinallcausecirrhosis
AT zhangyonghong individualsurveillancebycompetingriskmodelforpatientswithhepatocellularcarcinomaoccurrenceinallcausecirrhosis